Fuji Pharma, Oct-Dec (1Q) Ordinary Profit Turns to Profit

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Feb 6, 2025 4:00 pm JST Earnings

4554 Fuji Pharma Co.,Ltd. 【J-GAAP】

Earnings Report

Fuji Pharma Co.,Ltd. <4554> [TSE Prime] announced its financial results after the market closed on February 6th (16:00). The consolidated ordinary profit/loss for the first quarter of the fiscal year ending September 2025 (October to December) turned into a profit of 1.37 billion yen (compared to a loss of 0.09 billion yen in the same period last year). The progress rate toward the plan for the six months ending March (1H) of 2.33 billion yen was 59.1%, it was below the five-year average of 62.5%.

In the most recent three-month period, from October to December (1Q), the operating profit/loss margin drastically improved from -1.3% in the same period last year to 9.6%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Oct - Dec, 2022	9,996	1,190	1,579	1,114	45.9	64.3	Feb 9, 2023	J-GAAP
Oct - Dec, 2023	10,746	-140	-96	2,739	112.7	ー	Feb 8, 2024	J-GAAP
Oct - Dec, 2024	13,000	1,252	1,376	991	40.8	59.1	Feb 6, 2025	J-GAAP
YoY	+21.0%	－	－	-63.8%	-63.9%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	21,388	1,443	2,165	4,257	175.2	20	May 9, 2024	J-GAAP
Oct - Mar, 2024 Guidance	26,150	2,380	2,330	1,650	67.6	20	Nov 12, 2024	J-GAAP
YoY	+22.3%	+64.9%	+7.6%	-61.2%	-61.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2023	40,889	3,858	4,519	3,435	141.4	37	Nov 9, 2023	J-GAAP
Sep, 2024	46,138	3,880	4,445	6,146	252.9	42.50	Nov 12, 2024	J-GAAP
Sep, 2025 Guidance	53,360	4,850	4,680	3,380	138.4	45.50	Nov 12, 2024	J-GAAP
YoY	+15.7%	+25.0%	+5.3%	-45.0%	-45.3%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	10,746	-140	-96	2,739	112.7	-1.3	Feb 8, 2024	J-GAAP
Jan - Mar, 2024	10,642	1,583	2,261	1,518	62.5	14.9	May 9, 2024	J-GAAP
Apr - Jun, 2024	11,767	772	802	653	26.9	6.6	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	12,983	1,665	1,478	1,236	50.9	12.8	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	13,000	1,252	1,376	991	40.8	9.6	Feb 6, 2025	J-GAAP
YoY	+21.0%	－	－	-63.8%	-63.9%